Key Insights

Highlights

Success Rate

88% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

6.7%

1 terminated out of 15 trials

Success Rate

87.5%

+0.9% vs benchmark

Late-Stage Pipeline

7%

1 trials in Phase 3/4

Results Transparency

0%

0 of 7 completed with results

Key Signals

88% success

Data Visualizations

Phase Distribution

11Total
Not Applicable (5)
P 1 (5)
P 3 (1)

Trial Status

Completed7
Recruiting2
Unknown2
Not Yet Recruiting1
Withdrawn1
Terminated1

Trial Success Rate

87.5%

Benchmark: 86.6%

Based on 7 completed trials

Clinical Trials (15)

Showing 15 of 15 trials
NCT05405296CompletedPrimary

Evaluation of the Truenat™MTB Plus/COVID-19 Test for TB (Tuberculosis) and COVID-19 (SARS-CoV2)

NCT07609264Not Yet RecruitingPrimary

TB Stigma in the UK: Patients Experiences and Everyday Responses

NCT07164742Not ApplicableRecruiting

Parent Study Name: Pulmonary Rehabilitation to Reduce Post-Tuberculosis Morbidity (TB Pure)

NCT04298905Not ApplicableActive Not Recruiting

Leveraging mHealth to Enable and Adapt CHW Strategies to Improve TB/HIV Patient Outcomes in SA

NCT06701110Phase 1RecruitingPrimary

Pharmacokinetic Study of Sudapyridine(WX-081)in Healthy Chinese Subjects

NCT04645836Not ApplicableCompleted

Impact of a Pharmacist-led Patient-centred Care Intervention Along With Text-Message Reminders, on the Management of Newly Diagnosed Tubercular Patients: a Protocol for a Randomized Controlled Trial'.

NCT04673227Unknown

Cytometric Immunodiagnostics of Latent Tuberculosis Infection (LTBI)

NCT03208725Unknown

Childhood Acute Illness and Nutrition Network

NCT00424684Not ApplicableWithdrawn

Comparison of the Quantiferon®-TB GOLD (in Tube) Assay With Tuberculin Skin Testing for Detecting Latent Tuberculosis Infection in Patients With Chronic Liver Disease Being Evaluated for or Awaiting Liver Transplantation

NCT01055145Phase 3TerminatedPrimary

Comparison of the Effect Between Levofloxacin and Moxifloxacin Among MDR-TB Patients

NCT00480558Phase 1Completed

A Study of MVA85A, in Asymptomatic Volunteers Infected With TB, HIV or Both

NCT00480454Phase 1CompletedPrimary

Safety, Immunogenicity, and Impact of MVA85A, on the Immunogenicity of the EPI Vaccines

NCT00654316Phase 1CompletedPrimary

Study of the Safety and Immunogenicity of Bacille Calmette Guerin (BCG) Vaccine

NCT00480688Phase 1CompletedPrimary

A Study of the Immunogenicity of M. Bovis BCG, Delivered Intradermally in Healthy Volunteers

NCT00480714Not ApplicableCompletedPrimary

A Study of the Immunogenicity of BCG, Delivered Intradermally in Healthy Volunteers

Showing all 15 trials

Research Network

Activity Timeline